Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: HLN )

8.840 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 8.740 (1)
Ask (Size) 8.930 (1)
Prev. Close 8.840
Today's Range 8.840 - 8.840
52wk Range 7.695 - 8.995
Shares Outstanding N/A
Dividend Yield 1.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... 
Via Benzinga

Performance

YTD
+7.41%
+7.41%
1 Month
+2.31%
+2.31%
3 Month
+5.11%
+5.11%
6 Month
+6.63%
+6.63%
1 Year
+1.49%
+1.49%

More News

Read More
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
Via Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Via Benzinga
Current Analysis: Haleon
Via Talk Markets
Earnings Scheduled For February 29, 2024
Via Benzinga
Haleon Earnings Preview
Via Benzinga
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
Via Benzinga
Robitussin Recall 2024: What to Know About the New Cough Syrup Recalls
Via InvestorPlace
Peering Into Haleon's Recent Short Interest
Via Benzinga
How Is The Market Feeling About Haleon?
Via Benzinga
Looking Into Haleon's Recent Short Interest
Via Benzinga
Robitussin Recall: Here Are The Products Impacted And What You Need To Know
Via Benzinga
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
Via Benzinga
3 cheap 'stock'-ing stuffers Wall Street is bullish on
Via MarketBeat
Topics Stocks
Exposures US Equities
Health exclusion affects more than three in five people globally
From Haleon
Via GlobeNewswire
How Is The Market Feeling About Haleon?
Via Benzinga
A Look Into Haleon Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Haleon?
Via Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Via Benzinga
7 Healthcare Stocks to invest in for a Healthy Future
Via InvestorPlace
GSK: Pharma Giant Prioritizing Shareholder Dividends
Via Talk Markets
Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger, Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks, Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.